These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 39073766

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
    Blanco-Martín T, Alonso-García I, González-Pinto L, Outeda-García M, Guijarro-Sánchez P, López-Hernández I, Pérez-Vázquez M, Aracil B, López-Cerero L, Fraile-Ribot P, Oliver A, Vázquez-Ucha JC, Beceiro A, Bou G, Arca-Suárez J, GEMARA/SEIMC-CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT).
    Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.
    Blanco-Martín T, López-Hernández I, Aracil B, González-Pinto L, Aja-Macaya P, Alonso-García I, Rodríguez-Pallares S, Sánchez-Peña L, Outeda-García M, Pérez-Vázquez M, Vázquez-Ucha JC, Beceiro A, Pascual Á, Bou G, López-Cerero L, Oteo-Iglesias J, Arca-Suárez J, GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT).
    Antimicrob Agents Chemother; 2024 Oct 09; ():e0092424. PubMed ID: 39382274
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Resistance to ceftazidime-avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study.
    Valzano F, La Bella G, Lopizzo T, Curci A, Lupo L, Morelli E, Mosca A, Marangi M, Melfitano R, Rollo T, De Nittis R, Arena F.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0426623. PubMed ID: 38934607
    [Abstract] [Full Text] [Related]

  • 8. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.
    Jacobs MR, Abdelhamed AM, Good CE, Mack AR, Bethel CR, Marshall S, Hujer AM, Hujer KM, Patel R, van Duin D, Fowler VG, Rhoads DD, Six DA, Moeck G, Uehara T, Papp-Wallace KM, Bonomo RA.
    Antimicrob Agents Chemother; 2024 Sep 04; 68(9):e0075124. PubMed ID: 39133021
    [Abstract] [Full Text] [Related]

  • 9. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
    Meletiadis J, Paranos P, Georgiou PC, Vourli S, Antonopoulou S, Michelaki A, Vagiakou E, Pournaras S.
    Int J Antimicrob Agents; 2021 Nov 04; 58(5):106440. PubMed ID: 34551356
    [Abstract] [Full Text] [Related]

  • 10. Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.
    Le Terrier C, Nordmann P, Freret C, Seigneur M, Poirel L.
    Antimicrob Agents Chemother; 2023 Jul 18; 67(7):e0033923. PubMed ID: 37255469
    [Abstract] [Full Text] [Related]

  • 11. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Shortridge D, Castanheira M.
    Int J Antimicrob Agents; 2023 Apr 18; 61(4):106744. PubMed ID: 36738849
    [Abstract] [Full Text] [Related]

  • 12. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum β-lactamases.
    Le Terrier C, Nordmann P, Buchs C, Poirel L.
    Antimicrob Agents Chemother; 2024 Apr 03; 68(4):e0154823. PubMed ID: 38415988
    [Abstract] [Full Text] [Related]

  • 13. In vitro development of resistance against antipseudomonal agents: comparison of novel β-lactam/β-lactamase inhibitor combinations and other β-lactam agents.
    Castanheira M, Kimbrough JH, Lindley J, Doyle TB, Ewald JM, Sader HS.
    Antimicrob Agents Chemother; 2024 May 02; 68(5):e0136323. PubMed ID: 38526050
    [Abstract] [Full Text] [Related]

  • 14. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, Aja-Macaya P, Guijarro-Sánchez P, Rumbo-Feal S, Muíño-Andrade M, Fernández-González A, Martínez-Guitián M, Beceiro A, Rodríguez-Iglesias M, Oliver A, Arca-Suárez J, Galán-Sánchez F, Bou G.
    J Antimicrob Chemother; 2023 May 03; 78(5):1195-1200. PubMed ID: 36918743
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.
    Le Terrier C, Nordmann P, Poirel L.
    J Antimicrob Chemother; 2022 Dec 23; 78(1):101-107. PubMed ID: 36308322
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.
    Buyukyanbolu E, Genc L, Cyr EA, Karakus M, Comert F, Otlu B, Aktas E, Nicolau DP.
    Eur J Clin Microbiol Infect Dis; 2024 Sep 23; 43(9):1787-1794. PubMed ID: 38995343
    [Abstract] [Full Text] [Related]

  • 17. In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales.
    Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Totrov M, Loutit J, Dudley M.
    Antimicrob Agents Chemother; 2023 Nov 15; 67(11):e0044023. PubMed ID: 37800963
    [Abstract] [Full Text] [Related]

  • 18. Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
    Poirel L, Ortiz de la Rosa JM, Sadek M, Nordmann P.
    Antimicrob Agents Chemother; 2022 Apr 19; 66(4):e0003922. PubMed ID: 35315685
    [Abstract] [Full Text] [Related]

  • 19. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
    Boattini M, Comini S, Bianco G, Iannaccone M, Casale R, Cavallo R, Costa C.
    J Chemother; 2023 May 19; 35(3):198-204. PubMed ID: 35731718
    [Abstract] [Full Text] [Related]

  • 20. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D, Giske CG, Grāmatniece A, Abodakpi H, Tam VH, Leibovici L.
    Clin Microbiol Rev; 2020 Dec 16; 34(1):. PubMed ID: 33177185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.